129 Aufrufe 129 0 Kommentare 0 Kommentare

    Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure- Hagens Berman

    San Francisco, California--(Newsfile Corp. - June 19, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.

    Hagens Berman is investigating investors' claims and urges Iovance investors who suffered substantial losses to submit your losses now.

    Class Period: May 9, 2024 - May 8, 2025
    Lead Plaintiff Deadline: July 14, 2025
    Visit: www.hbsslaw.com/investor-fraud/iova
    Contact the Firm Now: IOVA@hbsslaw.com
    844-916-0895

    Bellemin's Exit Coincides with Amtagvi's Stumbles

    The formal notification of Mr. Bellemin's departure, tendered on June 10, 2025, aligns with the terms of his executive employment agreement. The San Carlos-headquartered biotech has yet to name a successor for the critical financial post, leaving a void as it navigates a challenging market and legal landscape.

    Mr. Bellemin's tenure concludes as Iovance confronts a series of operational and financial disappointments. The company's first-quarter sales figures for Amtagvi, its recently launched melanoma treatment, significantly underperformed Wall Street's expectations, compelling management to temper its full-year revenue projections. This revised outlook triggered a sharp reaction from analysts, including a downgrade from UBS.

    Litigation Compounds Commercial Challenges

    Adding to the complexity, Iovance finds itself defending against a securities fraud class action. The litigation centers on allegations regarding the company's portrayal of its authorized treatment centers (ATCs), which are crucial to Amtagvi's administration. The complaint alleges that Iovance had consistently highlighted ATCs as a primary driver of demand, asserting, for instance, that "ATCs continue to drive increasing demand for Amtagvi" and that a substantial majority of eligible patients were within a reasonable proximity of an ATC.

    Seite 1 von 2 




    newsfile
    0 Follower
    Autor folgen

    Verfasst von newsfile
    Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure- Hagens Berman San Francisco, California--(Newsfile Corp. - June 19, 2025) - Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, …